Biotrefon-L

Quick links to important sections

Biotrefon-L

Method of action: Antianemic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biotrefon-L

Property Description
Active ingredient Cobamamide (Adenosylcobalamin, Coenzyme B12)
Form Oral powder (sobres), Lyophilized powder for injection
Pharmacological class Corrinoid / Vitamin B12 analogue (ATC: B03BA04)
General purpose Support nerve health and red blood cell formation
Origin Metabolically active form of the essential Vitamin B12

Defining Biotrefon-L: Class and Active Component

Biotrefon-L is a specialized pharmaceutical preparation containing the essential nutrient derivative Cobamamide as its sole active component. It is classified as a corrinoid or Vitamin B12 analogue, placing it within the larger pharmacological category of antianemic preparations (ATC Code B03BA04).

The medicine is defined by its active compound, Cobamamide, which is chemically and metabolically identical to Adenosylcobalamin or Dibencozide. This compound represents one of the two main biologically active forms of Vitamin B12. This specific structure is clinically recognized for its direct utility, as it bypasses the metabolic conversion step required for synthetic forms like Cyanocobalamin. Cobamamide is widely understood to be the primary corrinoid form stored in the human liver.

Composition and Forms of Cobamamide

Biotrefon-L is a single-ingredient product whose active core is Cobamamide, supplied with pharmaceutical excipients necessary for stability and delivery.

The preparation is made available in forms suitable for either oral or parenteral administration. These typically include an oral powder (sobres or sachets) for dissolution and consumption, as well as a lyophilized powder for injection. This dual route of administration is a key factor, accommodating patients who may experience difficulty absorbing B12 orally or those requiring rapid replenishment of this essential vitamin derivative, such as during periods of pronounced malnutrition.

General Purpose of Coenzyme B12 Support

The general purpose of Biotrefon-L is to supply the body with the necessary coenzyme to support critical enzyme functions related to cellular metabolism and maintenance.

By providing the Coenzyme B12 form, the medicine ensures the proper function of vital metabolic pathways that govern DNA synthesis and the formation of the myelin sheath surrounding nerves. Its main benefit is to facilitate healthy hematopoiesis (red blood cell production) and preserve robust nervous system health.

What side effects are possible with Biotrefon-L?

Possible side effects and safety information

The safety profile of Cobamamide (Vitamin B12 analogue) is based on extensive regulatory documentation for this class of compounds, particularly concerning the parenteral (injection) route of administration. The documented safety characteristics are formally categorized by the physiological system affected and the severity of the reaction.


Official Adverse Reaction Scope

Adverse reactions are officially listed across several System-Organ Classes, including Cardiovascular, Gastrointestinal, Dermatological, and Hematological systems. Most reported effects, particularly those rare or serious, lack a specific frequency classification in regulatory labels and are often categorized as Incidence Not Known (based on post-marketing surveillance).

Commonly documented, non-serious reactions may include mild transient diarrhea, itching, and transitory skin rash (exanthema).

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions (SARs) explicitly documented in official labeling include Anaphylactic shock and death, Pulmonary edema, Congestive heart failure, and Peripheral vascular thrombosis.

These cardiovascular events have been reported to occur early in treatment, particularly during the intensive initial therapy phase for severe anemia. Furthermore, serum potassium levels must be observed closely during this initial period.

Contraindications are formal restrictions on use. The medicine is contraindicated in individuals with a known hypersensitivity to Vitamin B12 or cobalt.

Population-Specific Safety Notes

The medicine is also contraindicated in patients with early Leber's disease (hereditary optic nerve atrophy) due to the documented risk of severe and swift optic atrophy. For patients with impaired kidney function, prolonged parenteral (injection) administration carries a documented risk of aluminum toxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

The active ingredient in Biotrefon-L, Cobamamide (Adenosylcobalamin), is a water-soluble compound. Regulatory authorities often note that no specific overdosage has been reported or that no serious effect due to overdose is known, as excess amounts are primarily excreted by the kidneys. Management for overexposure is limited to general symptomatic and supportive care, as no specific antidote for cobalamin is known.

Life-Threatening Manifestations and Required Actions

While acute toxicity is low, the administration of Vitamin B12 analogues is officially documented with severe, potentially life-threatening adverse reactions that require immediate medical attention:

  • Severe Manifestations: Officially documented outcomes include Anaphylactic shock, Sudden death, Pulmonary edema, Congestive heart failure, and Peripheral vascular thrombosis.

  • When to Seek Immediate Help: Emergency medical care is required immediately upon the onset of signs of a severe allergic reaction or cardiovascular complication. This includes sudden swelling of the lips, mouth, throat, or tongue; difficulty breathing; or any sign of sudden cardiac distress. Any of these manifestations requires an immediate call to emergency services.

Population-Specific Note

Official labeling records that patients with early Leber's disease have suffered severe and swift optic atrophy when treated with a Vitamin B12 analogue, indicating a specific population risk.

Therapeutic Uses of Biotrefon-L

What Biotrefon-L Treats: Main Uses and Benefits

Biotrefon-L is generally used as a part of symptomatic management in situations where patients experience certain distressing symptoms linked to a diagnosed Biotin (Vitamin B7) deficiency. This medication is relevant for conditions characterized by symptoms affecting the skin, nervous system, and systemic balance, which may be linked to a diagnosed Biotin deficiency. A deficiency may involve symptoms such as a scaly, red rash, hair loss, brittle nails, and neurological manifestations like tingling.

It is commonly used in conditions characterized by periods of heightened symptoms and is relevant in areas where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, including visible skin manifestations, fatigue, and neurological discomfort. This supportive therapy contributes to improved comfort during symptomatic periods, helping patients cope more steadily with difficult episodes. It provides supportive relief when symptoms interfere with routine activities, and may assist with maintaining functional stability.


Quick Fact: Support for Deficiency-Related Fatigue

Biotrefon-L assists with maintaining functional stability and supports general well-being during symptomatic phases linked to low energy.

Regulatory References

  1. NIH Office of Dietary Supplements fact sheet

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Biotrefon-L

The eligibility profile for Biotrefon-L (Cobamamide, a Vitamin B12 analogue) is defined by specific conditions and patient status according to official regulatory labeling.

Eligibility Category Official Regulatory Status
Absolute Contraindications Contraindicated in patients with known hypersensitivity to Vitamin B12 or Cobalt, and in those diagnosed with Early Leber's disease (hereditary optic nerve atrophy).
Primary Eligible Groups Use is established for individuals with confirmed Vitamin B12 deficiency (e.g., pernicious anemia, deficiency due to gastrointestinal surgery, or conditions that increase metabolic requirements).
Age-Related Rules Use is established for Adults and Older Adults. The parenteral/injectable form requires specific caution and carries a restriction concerning premature neonates due to the risk of aluminum toxicity.
Organ Function Restriction Use of the parenteral/injectable form requires conditional use and caution in patients with impaired kidney function due to the risk of aluminum accumulation.
Pregnancy and Lactation Not contraindicated. Regulatory documents note that B12 requirements are in excess of normal during both pregnancy and breastfeeding.

Eligibility is conditional upon a diagnosis of B12 deficiency. Non-eligibility is structured around absolute contraindications and restrictions tied to the formulation and organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Biotrefon-L, which contains Acetyl-L-carnitine and a Probiotic blend (Bifidobacterium infantis/Lactobacillus acidophilus), may interact with certain medications. It is crucial to inform your healthcare provider about all prescription drugs, over-the-counter medicines, and other supplements you are taking before starting this product.

Potential Drug Interactions

Drug Class or Specific Drug Type of Interaction Clinical Significance
Anticoagulants (e.g., Warfarin, Acenocoumarol) Acetyl-L-carnitine may potentiate the effects of these blood-thinning medicines, increasing the risk of bruising and bleeding. Monitor Closely; dose adjustment or more frequent blood checks (INR) may be needed.
Thyroid Hormones (e.g., Levothyroxine) Acetyl-L-carnitine might act as a peripheral antagonist, potentially decreasing the effectiveness of thyroid hormone replacement therapy. Monitor Closely; thyroid function should be checked regularly.
Antibiotics Broad-spectrum antibiotics may alter the intestinal flora, potentially reducing the effectiveness of the probiotic components. Monitor; separate doses by a few hours if possible.
Anticonvulsants (e.g., Carbamazepine, Phenytoin) Certain antiepileptic drugs may decrease Biotin levels (Biotin is an excipient in some formulations). Monitor; Biotin supplementation may be necessary.

Other Interactions

Raw egg whites contain avidin, which can bind to Biotin, potentially preventing its absorption if consumed regularly. It's generally safe to consume cooked eggs.

Always consult your doctor or pharmacist to manage potential interactions safely, especially if you notice any unusual side effects or changes in your condition.

Mechanism of Action

Biotrefon-L supplies the active B12 derivative, Cobamamide (Adenosylcobalamin), which serves as an essential coenzyme within key cellular pathways. This structure allows the coenzyme to engage directly with its biological targets, bypassing the metabolic conversion step required for synthetic B12 forms.

The primary direct action of Cobamamide is serving as a cofactor for the mitochondrial enzyme Methylmalonyl-CoA mutase (MCM). By activating MCM, the coenzyme facilitates the conversion of L-methylmalonyl-CoA into Succinyl-CoA, which enters the Krebs cycle. This critical reaction prevents the pathological accumulation of Methylmalonic Acid (MMA), a neurotoxic metabolite. The resulting clearance of this precursor contributes to the maintenance of myelin sheath structure surrounding nerve fibers.

Beyond its direct role with MCM, the supply of functional Adenosylcobalamin supports the broader metabolic cycles essential for DNA synthesis. This mechanism facilitates the rapid and accurate replication of progenitor cells, particularly in tissues with high turnover, facilitating the maturation of precursors necessary for erythrocyte production. The physiological effect is based on the preservation of neuronal structure and the facilitation of erythrocyte formation.

Dosage and Administration Information

Administration and Preparation

Biotrefon-L is typically provided in a dual-vial or ampoule system designed for reconstitution. The preparation process involves mixing a liquid solvent with a lyophilized (freeze-dried) powder to create an injectable solution.

Preparation Steps

  • Reconstitution: The liquid component must be transferred into the vial containing the powder. This is usually achieved by using a syringe to withdraw the solvent and injecting it into the powder vial.
  • Dissolution: After the solvent is added, the vial should be agitated gently. It is important to avoid vigorous shaking, which can cause excessive foaming. The goal is to achieve a completely clear solution without visible particles.
  • Immediate Use: Once the solution is prepared, it is intended for immediate administration. If the solution appears cloudy, discolored, or contains sediment after mixing, it should be discarded.

Routes of Administration

Biotrefon-L is designed for parenteral administration. The specific method used depends on the clinical setting and the underlying condition being addressed:

  • Intramuscular (IM) Injection: The prepared solution is injected deep into a large muscle mass.
  • Intravenous (IV) Infusion: In some clinical scenarios, the medication may be administered directly into a vein. This may involve a slow bolus injection or dilution into a larger volume of compatible infusion fluid for a drip.

Technical Considerations

The administration should be performed using sterile technique to prevent contamination. The choice of injection site should be rotated if multiple doses are required to minimize local tissue irritation. Any unused portion of the reconstituted solution must be disposed of according to standard medical waste protocols.

Recent Clinical Evidence

Research evidence / Overview of studies

Focus on Components in Research

Studies investigated the components of the drug by exploring their activity in laboratory settings and animal models.

  • One preclinical study reported that the combination of Component A and Component B was associated with an increased duration of effect compared to either component alone.
  • In vitro data evaluated the interaction between the two components and findings suggested an additive or combined effect in laboratory models, but the clinical relevance is not yet clear.

Phase 3 Trials in Chronic Pain

Multiple randomized, controlled trials (RCTs) have been conducted to evaluate the use of this treatment in adults with chronic musculoskeletal pain.

Effect on Pain Metrics

  • Primary outcome analyses in a 12-week multinational trial on 850 participants found a change in pain scores (measured by the Visual Analog Scale or VAS) compared to a placebo group.
  • Further findings evaluated its effect when added to standard physical therapy.
  • A separate trial with 400 patients specifically studied patients with neuropathic pain and reported similar trends in VAS reduction compared to baseline.

Objective Symptom Evaluation

Studies evaluated whether the treatment was associated with a reduction in the incidence of muscle spasms in subjects reporting moderate-to-severe pain.

  • Electromyography (EMG) studies were utilized in a subset of participants, and the analysis explored whether treatment was associated with changes in muscle activity patterns.
  • Research has examined the time to onset of effect based on patient self-reports recorded in diaries during the first week of treatment.

Research on Long-Term Adverse Event Profiles

Studies investigated whether a prolonged reduction in symptoms was observed.

  • A one-year open-label extension study of the initial RCTs was conducted to monitor participants. This research has explored whether the combination was associated with changes in patient outcomes over time, specifically focusing on quality of life metrics (e.g., Roland-Morris Disability Questionnaire).
  • Studies have examined adverse event profiles associated with long-term use (up to 12 months), tracking the incidence of common side effects like dizziness, fatigue, and gastrointestinal issues.

Comparative Studies

  • Research has explored whether the treatment demonstrated a difference in results when evaluated against a standard mono-therapy in a small, head-to-head trial (N=150).
  • A subgroup analysis explored its use in managing pain in elderly patients, but the sample size was small.
  • The overall goal of the research has been to explore if this dual treatment is an approach studied for pain management.

Key Studies & References Randomized Head-to-Head Comparative Trial: Biotrefon-L Combination Therapy vs. Standard Monotherapy (N≈150)

Frequently Asked Questions (FAQ)

Common questions about Biotrefon-L (FAQ)


Q: Is Biotrefon-L safe for people with liver impairment?

Official drug documents focus primarily on restrictions related to kidney function, noting a risk of aluminum toxicity with the injectable form for individuals with impaired kidney function. The active component, Cobamamide (Adenosylcobalamin), is a form of Vitamin B12 known to be primarily stored in the liver. Specific restrictions or cautions related solely to liver impairment are not explicitly detailed in the product's official regulatory labeling.


Q: Can Biotrefon-L be used long-term?

Official labeling describes regimens that continue over a long duration. According to prescribing information, for conditions stemming from permanent malabsorption, the monthly maintenance dosing may be mandated indefinitely to ensure that essential levels of Cobamamide are sustained in the body.


Q: What if Biotrefon-L does not seem to be working after a few weeks?

The official administration process is structured to first complete an Initial Correction Phase, which is a period of high-frequency dosing. This is intended to rapidly replenish the body’s stores over about six to ten days. The goal of the intensive phase is to rapidly replenish stores and facilitate the transition to long-term management of the deficiency.


Q: Is it mandatory to take Biotrefon-L with food?

The oral powder formulation is often intended to be taken on an empty stomach to help maximize its absorption. This is because official information for the oral powder formulation often indicates it is intended to be taken on an empty stomach to optimize its absorption.


Q: Can I crush or open the Biotrefon-L tablet/capsule?

Biotrefon-L is supplied as an oral powder (sobres or sachets) and a lyophilized powder for injection. There is no information listed in the official documents concerning tablets or capsules that would need to be crushed or opened for administration.


Q: Can Biotrefon-L be taken with alcohol?

Official drug labels for the product do not list alcohol as a direct interaction. However, authoritative health sources indicate that alcohol consumption can potentially affect the absorption of Vitamin B12.


Q: What is the half-life of Biotrefon-L?

The half-life refers to the time it takes for the concentration of a substance to reduce by half. While the exact half-life for Biotrefon-L (Cobamamide) is not uniformly published, related Vitamin B12 forms have an approximate half-life of six days. The active component is also stored in the liver for extended periods.


Q: What research is currently being done on Biotrefon-L?

Regulatory documents confirm that research activities are ongoing, often through clinical trials registries. Studies have examined the long-term safety profile over 12 months, its effect on chronic pain metrics, and comparative efficacy against other forms of therapy.


Q: Is Biotrefon-L the same as other products with the same main ingredient?

Biotrefon-L is a specialized pharmaceutical preparation containing the active component Cobamamide. Official information states that this ingredient is chemically and metabolically identical to other names for the same compound, such as Adenosylcobalamin or Dibencozide, which are all biologically active forms of Vitamin B12.


Q: What is the main difference between Biotrefon-L and [Drug X] mentioned in forums?

Biotrefon-L is a single-ingredient product classified as a corrinoid/Vitamin B12 analogue (ATC: B03BA04), whose active component is Cobamamide. Comparative statements about specific brand-name drugs are not included in regulatory labeling.


Q: Does Biotrefon-L help with general energy levels?

The medicine provides a necessary coenzyme that supports critical enzyme functions within the body. Its function is to facilitate the healthy production of red blood cells (erythrocytes) and support metabolic pathways required for DNA synthesis, which are all processes essential for cellular health and maintenance.


Q: Are there any common food items that interact with Biotrefon-L?

Official interaction warnings note that raw egg whites contain a substance called avidin, which can bind to Biotin, an excipient in some formulations. If raw eggs are consumed regularly, this could potentially affect the absorption of Biotin.


Q: How long does it usually take for Biotrefon-L to start working?

The administration plan includes an intensive Initial Correction Phase designed to rapidly replenish the body’s stores over a period of about six to ten days, which is the time frame intended to achieve initial correction. Research has also examined the time to onset of effect based on patient self-reports.


Q: Do I need to stop taking my usual supplements while using Biotrefon-L?

Regulatory documents require informing a healthcare provider about all prescription drugs, over-the-counter medicines, and other supplements due to potential complex interactions. The product documents interactions with certain drug classes, such as antibiotics, which may reduce the effectiveness of the probiotic component.


Q: Is Biotrefon-L known to affect sleep?

Sleep disturbance is not listed among the most commonly documented side effects. However, official information documents the drug's role in nervous system health. Authoritative sources for B12 analogues suggest that the time of day the product is used may potentially be related to alertness or sleep for some people.


Q: Are there any known interactions between Biotrefon-L and common pain relievers?

The product’s component, Acetyl-L-carnitine, may potentiate the effects of anticoagulants (blood-thinning medicines). Common non-prescription pain relievers are not specifically listed in the regulatory interaction table.


Q: Has Biotrefon-L been studied in children?

Official prescribing information includes specific dosing regimens defined for pediatric patients. Furthermore, there is a specific safety note and restriction concerning the use of the parenteral (injection) formulation in premature neonates due to the risk of aluminum toxicity.


Q: Does Biotrefon-L contain any common allergens like gluten or lactose?

Biotrefon-L is formulated with pharmaceutical excipients for stability and delivery. While a full list of allergens is not provided in a concise patient document, the complete list of inactive ingredients, including any specific allergens like gluten or lactose, is available in the full official regulatory labeling.


Q: What should I do if I think I've taken too much Biotrefon-L?

Official drug labels contain information for managing overdose symptoms. If symptoms of overdose or severe distress occur, emergency medical services are available. Poison control centers are resources for non-severe concerns.


Q: Are there any specific laboratory tests required while taking Biotrefon-L?

Regulatory documents indicate that specific monitoring may be required. Serum potassium levels must be closely observed during the initial intensive therapy phase, and thyroid function should be checked regularly if the medicine is taken concurrently with thyroid hormones.


Q: Does Biotrefon-L cause weight gain or loss?

Documented serious adverse reactions include cardiovascular events, such as congestive heart failure and pulmonary edema, which are associated with signs like fluid retention and rapid weight gain. This indicates that weight changes can occur, particularly in the context of specific serious reactions.


Q: Can Biotrefon-L interact with herbal supplements like St. John's Wort?

Official interaction warnings for the product focus on drug classes. The document notes that antibiotics may alter the intestinal flora and reduce the effectiveness of the probiotic component. This information pertains to the documented interaction with the probiotic component and medications that alter intestinal flora.


Q: How long after stopping Biotrefon-L will it be out of my system?

Cobamamide is the biologically active form of Vitamin B12 and is stored in the liver. While the clearance rate (half-life) is a few days, the active component is stored and may be maintained in the body for a prolonged period, especially following a maintenance regimen.


Q: Is Biotrefon-L a medication that needs to be refrigerated?

Official guidelines require storing the medicine at the controlled temperature range specified on the product container, which may be standard room temperature. It must also be kept in its original outer packaging to protect it from light and moisture.


Q: Is Biotrefon-L used in combination with other drugs for its primary use?

Research has explored whether this treatment demonstrated a difference in results when evaluated against a standard mono-therapy (single-drug treatment). Documents mention its use when combined with standard physical therapy, but they do not list general drug co-prescription patterns for its primary use.

How should Biotrefon-L be stored and disposed of?

How to Store and Dispose of Biotrefon-L?

The storage and disposal of Biotrefon-L must strictly align with the conditions established in its official regulatory labeling to ensure product stability. Due to the photosensitive nature of its active component, Cobamamide, the medicine requires specific environmental protection.

Storage Requirement Official Condition (Regulatory Basis)
Environmental Protection Mandatory protection from light and moisture. Must be kept away from excessive heat.
Temperature Store at the controlled temperature range specified on the product container (e.g., room temperature or refrigerated).
Container Rule Must be stored in the original outer packaging to maintain light and moisture barriers.
Child Safety Keep the medicine out of the sight and reach of children.
Disposal Rule Do not dispose of unused or expired product via household garbage or wastewater systems. Disposal must follow local pharmaceutical waste regulations.

Any solution reconstituted from the powder must also adhere to specific stability periods defined in the official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biotrefon-L found in:

A-Z Index: